SK19292000A3 - Kompozícia na prevenciu a/alebo liečenie osteoporózy a zmien v dôsledku menopauzálneho syndrómu - Google Patents

Kompozícia na prevenciu a/alebo liečenie osteoporózy a zmien v dôsledku menopauzálneho syndrómu Download PDF

Info

Publication number: SK19292000A3
Authority: SK; Slovakia
Prior art keywords: carnitine; propionyl; genistein; acid; composition
Prior art date: 1998-06-23

Application number

SK1929-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Claudio Cavazza

Original Assignee

Sigma-Tau Healthscience S. P. A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-23

Filing date

1999-06-17

Publication date

2001-08-06

1999-06-17 Application filed by Sigma-Tau Healthscience S. P. A. filed Critical Sigma-Tau Healthscience S. P. A.

2001-08-06 Publication of SK19292000A3 publication Critical patent/SK19292000A3/sk

Links

239000000203 mixture Substances 0.000 title claims abstract description 55
TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 title claims abstract description 52
UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 title claims abstract description 45
235000006539 genistein Nutrition 0.000 title claims abstract description 45
229940045109 genistein Drugs 0.000 title claims abstract description 45
230000002265 prevention Effects 0.000 title abstract description 4
230000009245 menopause Effects 0.000 title abstract 2
208000011580 syndromic disease Diseases 0.000 title abstract 2
230000004075 alteration Effects 0.000 title 1
ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims abstract description 44
CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 25
235000008696 isoflavones Nutrition 0.000 claims abstract description 25
208000001132 Osteoporosis Diseases 0.000 claims abstract description 10
GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 10
235000015872 dietary supplement Nutrition 0.000 claims abstract description 7
239000003814 drug Substances 0.000 claims abstract description 7
PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 36
235000010469 Glycine max Nutrition 0.000 claims description 20
229960004203 carnitine Drugs 0.000 claims description 20
239000002253 acid Substances 0.000 claims description 16
ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 11
-1 isovaleryl Chemical group 0.000 claims description 9
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
244000068988 Glycine max Species 0.000 claims description 6
206010027304 Menopausal symptoms Diseases 0.000 claims description 5
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
229910019142 PO4 Inorganic materials 0.000 claims description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
229940009098 aspartate Drugs 0.000 claims description 4
235000007240 daidzein Nutrition 0.000 claims description 4
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
239000010452 phosphate Substances 0.000 claims description 4
VSNFQQXVMPSASB-SNVBAGLBSA-N O-valeroyl-L-carnitine Chemical compound CCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VSNFQQXVMPSASB-SNVBAGLBSA-N 0.000 claims description 3
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 3
229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
239000011707 mineral Substances 0.000 claims description 3
239000000419 plant extract Substances 0.000 claims description 3
229930003231 vitamin Natural products 0.000 claims description 3
239000011782 vitamin Substances 0.000 claims description 3
235000013343 vitamin Nutrition 0.000 claims description 3
229940088594 vitamin Drugs 0.000 claims description 3
NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
239000003963 antioxidant agent Substances 0.000 claims description 2
235000006708 antioxidants Nutrition 0.000 claims description 2
239000005515 coenzyme Substances 0.000 claims description 2
235000004426 flaxseed Nutrition 0.000 claims description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
229940095064 tartrate Drugs 0.000 claims description 2
229940066528 trichloroacetate Drugs 0.000 claims description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
239000007787 solid Substances 0.000 claims 4
239000002775 capsule Substances 0.000 claims 2
239000008187 granular material Substances 0.000 claims 2
239000007788 liquid Substances 0.000 claims 2
239000006187 pill Substances 0.000 claims 2
239000006188 syrup Substances 0.000 claims 2
235000020357 syrup Nutrition 0.000 claims 2
239000003826 tablet Substances 0.000 claims 2
230000001225 therapeutic effect Effects 0.000 abstract description 4
239000004480 active ingredient Substances 0.000 abstract description 2
230000000694 effects Effects 0.000 description 18
239000000284 extract Substances 0.000 description 17
150000002515 isoflavone derivatives Chemical class 0.000 description 15
RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 14
IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 description 13
235000020712 soy bean extract Nutrition 0.000 description 12
241001465754 Metazoa Species 0.000 description 10
239000003075 phytoestrogen Substances 0.000 description 10
102000004067 Osteocalcin Human genes 0.000 description 8
108090000573 Osteocalcin Proteins 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
210000000963 osteoblast Anatomy 0.000 description 8
241000700159 Rattus Species 0.000 description 7
210000000988 bone and bone Anatomy 0.000 description 7
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
238000003556 assay Methods 0.000 description 6
230000012010 growth Effects 0.000 description 6
230000002195 synergetic effect Effects 0.000 description 6
238000012360 testing method Methods 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 5
229960001123 epoprostenol Drugs 0.000 description 5
229960005309 estradiol Drugs 0.000 description 5
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
208000026310 Breast neoplasm Diseases 0.000 description 4
241000196324 Embryophyta Species 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
210000000481 breast Anatomy 0.000 description 4
230000007423 decrease Effects 0.000 description 4
229930182833 estradiol Natural products 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
238000000034 method Methods 0.000 description 4
229940094443 oxytocics prostaglandins Drugs 0.000 description 4
150000003180 prostaglandins Chemical class 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
102000013275 Somatomedins Human genes 0.000 description 3
229930003316 Vitamin D Natural products 0.000 description 3
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000000262 estrogen Substances 0.000 description 3
229940011871 estrogen Drugs 0.000 description 3
235000013305 food Nutrition 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
235000021374 legumes Nutrition 0.000 description 3
229930013686 lignan Natural products 0.000 description 3
235000009408 lignans Nutrition 0.000 description 3
150000005692 lignans Chemical class 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
210000003024 peritoneal macrophage Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
235000019166 vitamin D Nutrition 0.000 description 3
239000011710 vitamin D Substances 0.000 description 3
150000003710 vitamin D derivatives Chemical class 0.000 description 3
229940046008 vitamin d Drugs 0.000 description 3
RJFAYQIBOAGBLC-UHFFFAOYSA-N 2-amino-4-methylselanyl-butanoic acid Chemical compound C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 2
AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
208000005189 Embolism Diseases 0.000 description 2
102000018997 Growth Hormone Human genes 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
208000001435 Thromboembolism Diseases 0.000 description 2
229930003268 Vitamin C Natural products 0.000 description 2
229930003427 Vitamin E Natural products 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
230000010072 bone remodeling Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000007211 cardiovascular event Effects 0.000 description 2
235000013339 cereals Nutrition 0.000 description 2
229940031192 coenzyme Q10 10 mg Drugs 0.000 description 2
ZZIALNLLNHEQPJ-UHFFFAOYSA-N coumestrol Chemical compound C1=C(O)C=CC2=C1OC(=O)C1=C2OC2=CC(O)=CC=C12 ZZIALNLLNHEQPJ-UHFFFAOYSA-N 0.000 description 2
230000037213 diet Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
230000001076 estrogenic effect Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
238000002657 hormone replacement therapy Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000007689 inspection Methods 0.000 description 2
229930013032 isoflavonoid Natural products 0.000 description 2
150000003817 isoflavonoid derivatives Chemical class 0.000 description 2
235000012891 isoflavonoids Nutrition 0.000 description 2
230000007774 longterm Effects 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
230000001582 osteoblastic effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
235000019154 vitamin C Nutrition 0.000 description 2
239000011718 vitamin C Substances 0.000 description 2
235000019165 vitamin E Nutrition 0.000 description 2
229940046009 vitamin E Drugs 0.000 description 2
239000011709 vitamin E Substances 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006220 Breast cyst Diseases 0.000 description 1
206010049872 Breast discomfort Diseases 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
DWONJCNDULPHLV-HOTGVXAUSA-N Enterodiol Chemical compound C([C@@H](CO)[C@H](CO)CC=1C=C(O)C=CC=1)C1=CC=CC(O)=C1 DWONJCNDULPHLV-HOTGVXAUSA-N 0.000 description 1
AOJXPBNHAJMETF-UHFFFAOYSA-N Enterodiol Natural products OCC(Cc1ccc(O)cc1)C(CO)Cc2ccc(O)cc2 AOJXPBNHAJMETF-UHFFFAOYSA-N 0.000 description 1
HVDGDHBAMCBBLR-UHFFFAOYSA-N Enterolactone Natural products OC1=CC=CC(CC2C(C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-UHFFFAOYSA-N 0.000 description 1
108010085330 Estradiol Receptors Proteins 0.000 description 1
102100038595 Estrogen receptor Human genes 0.000 description 1
229940102550 Estrogen receptor antagonist Drugs 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
240000004658 Medicago sativa Species 0.000 description 1
235000010624 Medicago sativa Nutrition 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
206010030247 Oestrogen deficiency Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
244000042324 Trifolium repens Species 0.000 description 1
235000010729 Trifolium repens Nutrition 0.000 description 1
102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
206010046798 Uterine leiomyoma Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
208000021017 Weight Gain Diseases 0.000 description 1
241000212749 Zesius chrysomallus Species 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
230000032683 aging Effects 0.000 description 1
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
102000001307 androgen receptors Human genes 0.000 description 1
108010080146 androgen receptors Proteins 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
230000000923 atherogenic effect Effects 0.000 description 1
229940069765 bean extract Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
UIAFKZKHHVMJGS-UHFFFAOYSA-N beta-resorcylic acid Natural products OC(=O)C1=CC=C(O)C=C1O UIAFKZKHHVMJGS-UHFFFAOYSA-N 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
230000004097 bone metabolism Effects 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000007665 chronic toxicity Effects 0.000 description 1
231100000160 chronic toxicity Toxicity 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001120 cytoprotective effect Effects 0.000 description 1
KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
235000020669 docosahexaenoic acid Nutrition 0.000 description 1
KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
229960005135 eicosapentaenoic acid Drugs 0.000 description 1
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
HVDGDHBAMCBBLR-WMLDXEAASA-N enterolactone Chemical compound OC1=CC=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-WMLDXEAASA-N 0.000 description 1
235000019126 equol Nutrition 0.000 description 1
ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000003687 estradiol congener Substances 0.000 description 1
102000015694 estrogen receptors Human genes 0.000 description 1
108010038795 estrogen receptors Proteins 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
150000002338 glycosides Chemical group 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000002555 ionophore Substances 0.000 description 1
230000000236 ionophoric effect Effects 0.000 description 1
201000010260 leiomyoma Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
235000021388 linseed oil Nutrition 0.000 description 1
239000000944 linseed oil Substances 0.000 description 1
230000002248 lipoperoxidative effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000036651 mood Effects 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000001599 osteoclastic effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
102000003998 progesterone receptors Human genes 0.000 description 1
108090000468 progesterone receptors Proteins 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
150000003815 prostacyclins Chemical class 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
235000021283 resveratrol Nutrition 0.000 description 1
229940016667 resveratrol Drugs 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
235000003687 soy isoflavones Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
208000025421 tumor of uterus Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
208000010579 uterine corpus leiomyoma Diseases 0.000 description 1
201000007954 uterine fibroid Diseases 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

SK1929-2000A 1998-06-23 1999-06-17 Kompozícia na prevenciu a/alebo liečenie osteoporózy a zmien v dôsledku menopauzálneho syndrómu SK19292000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT98RM000417A IT1299191B1 (it)	1998-06-23	1998-06-23	Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa
PCT/IT1999/000174 WO1999066913A2 (en)	1998-06-23	1999-06-17	Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome, comprising propionyl-l-carnitine and genistein

Publications (1)

Publication Number	Publication Date
SK19292000A3 true SK19292000A3 (sk)	2001-08-06

Family

ID=11406005

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1929-2000A SK19292000A3 (sk)	1998-06-23	1999-06-17	Kompozícia na prevenciu a/alebo liečenie osteoporózy a zmien v dôsledku menopauzálneho syndrómu

Country Status (27)

Country	Link
US (1)	US6335038B1 (de)
EP (1)	EP1089742B1 (de)
JP (1)	JP4430233B2 (de)
KR (1)	KR20010071541A (de)
CN (1)	CN1306434A (de)
AR (1)	AR018924A1 (de)
AT (1)	ATE228367T1 (de)
AU (1)	AU755272B2 (de)
BR (1)	BR9911440A (de)
CA (1)	CA2334875C (de)
DE (1)	DE69904172T2 (de)
DK (1)	DK1089742T3 (de)
EE (1)	EE200000741A (de)
ES (1)	ES2188177T3 (de)
HU (1)	HU224957B1 (de)
IL (1)	IL140163A0 (de)
IS (1)	IS5764A (de)
IT (1)	IT1299191B1 (de)
MA (1)	MA26655A1 (de)
NO (1)	NO20006431L (de)
NZ (1)	NZ508877A (de)
PL (1)	PL192118B1 (de)
PT (1)	PT1089742E (de)
SK (1)	SK19292000A3 (de)
TN (1)	TNSN99132A1 (de)
TR (1)	TR200003735T2 (de)
WO (1)	WO1999066913A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1302863B1 (it) *	1998-11-13	2000-10-10	Sigma Tau Healthscience Spa	Composizione ad attivita' antiossidante e preventiva di alterazionitrombotiche e aterosclerotiche comprendente una carnitina ed un
US6476010B2 (en)	2000-03-10	2002-11-05	Hill's Pet Nutrition	Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals
US20010039296A1 (en) *	2000-03-23	2001-11-08	Debasis Bagchi	Method and composition for preventing or reducing the symptoms of menopause
US20020076470A1 (en)	2000-10-31	2002-06-20	Colgate-Palmolive Company	Composition and method
US8669282B2 (en)	2000-10-31	2014-03-11	Hill's Pet Nutrition, Inc.	Companion animal compositions including lipoic acid and methods of use thereof
IT1317079B1 (it)	2000-12-21	2003-05-26	Sigma Tau Ind Farmaceuti	Uso della isovaleril l-carnitina per la preparazione di un medicamentoper la prevenzione e cura dell'osteoporosi.
BR0207948A (pt) *	2001-03-09	2004-07-27	Produits Nestel S A Soc D	Composição que melhora os déficits fisiológicos relacionados com a idade e que aumenta a longevidade
EP1370257B1 (de) *	2001-03-15	2007-07-25	DSM IP Assets B.V.	ZUSAMMENSETZUNG ZUR PRÄVENTION VON OSTEOPOROSE bestehend aus EINER KOMBINATION AUS ISOFLAVONEN UND POLYUNGESÄTTIGTEN FETTSÄUREN
AUPR957001A0 (en) *	2001-12-19	2002-01-24	Novogen Research Pty Ltd	Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
US20050090457A1 (en) *	2002-02-15	2005-04-28	N.V. Nutricia	Method of treating mammals with genistein and/or genistein analogues
KR100542478B1 (ko) *	2002-08-28	2006-01-11	한경대학교 산학협력단	석류 유래 피토에스트로겐을 함유하는 건강기능식품
KR20050057286A (ko) *	2002-09-09	2005-06-16	네스텍소시에테아노님	피부 성질을 개선시키기 위한 경구적으로 투여가능한 조성물
KR100520408B1 (ko) *	2003-03-25	2005-10-10	주식회사 태평양	비만개선용 조성물
CN103211806B (zh) *	2003-05-27	2015-09-09	帝斯曼知识产权资产管理有限公司	新颖的营养药物性组合物及其用途
JP2005187454A (ja) *	2003-12-05	2005-07-14	Sankyo Co Ltd	ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物
KR20060132667A (ko) *	2004-01-28	2006-12-21	네스텍소시에테아노님	피부 상태 개선 및 피부 질환 예방을 위한 영양 조성물
US7666913B2 (en)	2004-02-03	2010-02-23	Kotosugi Inc.	Method of treating or preventing osteoporosis using isotaxiresinol derived from Taxus yunnanensis
US8193240B2 (en) *	2004-03-17	2012-06-05	Nestec S.A.	Compositions and methods for reducing or preventing obesity
CN100351248C (zh) *	2004-07-05	2007-11-28	南京大学	染料木素衍生物及其制法和用途
US8697139B2 (en)	2004-09-21	2014-04-15	Frank M. Phillips	Method of intervertebral disc treatment using articular chondrocyte cells
DE102004060314A1 (de) *	2004-12-08	2006-08-31	Beiersdorf Ag	Wirkstoffkombinationen aus einem oder mehreren Isoflavonoiden und Carnitin und/oder einem oder mehreren Acyl-Carnitinen
BRPI0519642A8 (pt)	2004-12-29	2017-10-03	Hill´S Pet Nutrition Inc	Método para inibir um declínio em aprendizagem e/ou memória, kit apropriado para administrar um ou mais antioxidantes a um animal, meio para transmitir informação, e, uso de uma composição
US20080057140A1 (en) *	2005-01-10	2008-03-06	Mikko Unkila	Use of a Lignan for the Manufacture of a Composition for Preventing or Alleviating of Symptoms Relating to Estrogen Deficiency
DE102005011779A1 (de) *	2005-03-11	2006-09-14	Bayer Healthcare Ag	Endoparasitizide Mittel
WO2007006672A1 (en) *	2005-07-08	2007-01-18	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
BRPI0613000A2 (pt)	2005-07-14	2012-12-04	Hills Pet Nutrition Inc	método para aumentar a longevidade de um animal, artigo de fabricação, kit, e, meio de comunicação de informação acerca de ou instruções para a administração a um animal velho de uma composição
CN1939534B (zh) *	2005-09-27	2010-12-01	长春金赛药业股份有限公司	含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
WO2007042272A2 (en) *	2005-10-14	2007-04-19	Dsm Ip Assets B.V.	Use of a nutraceutical composition comprising resveratrol for the treatment of age-related diseases
EP1956923A1 (de)	2005-11-02	2008-08-20	Nestec S.A.	Isoflavonzusammensetzungen für die verringerung der anhäufung von körperfett in männlichen säugetieren und verfahren zu ihrer verwendung
US20090221690A1 (en)	2006-02-28	2009-09-03	Council Of Scientific And Industrial Research	Pharmaceutical Composition for the Prevention/Treatment of Bone Disorders and a Process for the Preparation Thereof
US8242100B2 (en)	2006-02-28	2012-08-14	Nestec Sa	Compositions and methods for inducing bone growth and inhibiting bone loss
JP2009534317A (ja) *	2006-04-12	2009-09-24	ユニリーバー・ナームローゼ・ベンノートシヤープ	皮膚に対する抗老化効果を有する経口組成物
EP2004161B8 (de) *	2006-04-12	2013-04-17	Unilever PLC	Orale zusammensetzung mit dha und genistein zur verbesserung der hauteigenschaften
WO2007116027A1 (en) *	2006-04-12	2007-10-18	Unilever Plc	Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin
US20080108696A1 (en) *	2006-08-02	2008-05-08	Brinton Roberta D	Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases
US8680140B2 (en) *	2006-08-02	2014-03-25	University Of Southern California	Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms
WO2008100560A2 (en) *	2007-02-14	2008-08-21	University Of Southern California	Estrogen receptor modulators, associated pharmaceutical compositions and methods of use
DK2343292T3 (da)	2008-09-10	2014-11-03	Asahi Glass Co Ltd	Nyt prostaglandin 12-derivat
US20110091435A1 (en) *	2008-10-24	2011-04-21	University Of Southern California	Phytoestrogenic formulations for alleviation or prevention of hair loss
JP2012508267A (ja) *	2008-11-11	2012-04-05	シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ	セルライトの処置に有用な化合物
KR101158856B1 (ko)	2009-05-12	2012-06-25	한국생명공학연구원	콩잎 추출물 또는 이의 분획물을 유효성분으로 함유하는 비만, 고지혈증, 동맥경화, 지방간, 당뇨 또는 대사증후군의 예방 또는 치료용 조성물
WO2011111714A1 (ja) *	2010-03-08	2011-09-15	科研製薬株式会社	新規なｅｐ４アゴニスト
EP2582368B1 (de) *	2010-06-16	2018-05-09	Alfasigma S.p.A.	Acetyl-L-carnitin zur Erhöhung der Neurogenese in neuronalem Gewebe
WO2012011572A1 (ja) *	2010-07-23	2012-01-26	国立大学法人大阪大学	拡張不全型心不全治療薬
IT201700116392A1 (it) *	2018-04-03	2019-10-03		Composizione per somministrazione orale aventi benefico effetto sulla salute della donna in menopausa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1275434B (it) *	1995-05-19	1997-08-07	Farmila Farma Milano	Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
IT1276225B1 (it) *	1995-10-17	1997-10-27	Sigma Tau Ind Farmaceuti	Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US5702752A (en) *	1996-03-13	1997-12-30	Archer Daniels Midland Company	Production of isoflavone enriched fractions from soy protein extracts
US6139872A (en) *	1996-08-14	2000-10-31	Henkel Corporation	Method of producing a vitamin product
EP1021177A4 (de) *	1997-02-04	2002-05-15	John V Kosbab	Zusammensetzungen und verfahren zur verhütung und behandlung von vaskulär-degeneratieve krankheiten

1998
- 1998-06-23 IT IT98RM000417A patent/IT1299191B1/it active IP Right Grant
1999
- 1999-06-17 PT PT99926749T patent/PT1089742E/pt unknown
- 1999-06-17 BR BR9911440-2A patent/BR9911440A/pt not_active IP Right Cessation
- 1999-06-17 NZ NZ508877A patent/NZ508877A/xx not_active Application Discontinuation
- 1999-06-17 KR KR1020007014485A patent/KR20010071541A/ko not_active Withdrawn
- 1999-06-17 HU HU0102879A patent/HU224957B1/hu not_active IP Right Cessation
- 1999-06-17 EE EEP200000741A patent/EE200000741A/xx unknown
- 1999-06-17 TR TR2000/03735T patent/TR200003735T2/xx unknown
- 1999-06-17 JP JP2000555599A patent/JP4430233B2/ja not_active Expired - Fee Related
- 1999-06-17 EP EP99926749A patent/EP1089742B1/de not_active Expired - Lifetime
- 1999-06-17 AT AT99926749T patent/ATE228367T1/de active
- 1999-06-17 CA CA002334875A patent/CA2334875C/en not_active Expired - Fee Related
- 1999-06-17 PL PL345030A patent/PL192118B1/pl unknown
- 1999-06-17 SK SK1929-2000A patent/SK19292000A3/sk unknown
- 1999-06-17 US US09/720,237 patent/US6335038B1/en not_active Expired - Lifetime
- 1999-06-17 ES ES99926749T patent/ES2188177T3/es not_active Expired - Lifetime
- 1999-06-17 MA MA25636A patent/MA26655A1/fr unknown
- 1999-06-17 AU AU43909/99A patent/AU755272B2/en not_active Ceased
- 1999-06-17 IL IL14016399A patent/IL140163A0/xx unknown
- 1999-06-17 WO PCT/IT1999/000174 patent/WO1999066913A2/en not_active Ceased
- 1999-06-17 CN CN99807767A patent/CN1306434A/zh active Pending
- 1999-06-17 DK DK99926749T patent/DK1089742T3/da active
- 1999-06-17 DE DE69904172T patent/DE69904172T2/de not_active Expired - Lifetime
- 1999-06-23 TN TNTNSN99132A patent/TNSN99132A1/fr unknown
- 1999-06-23 AR ARP990103006A patent/AR018924A1/es unknown
2000
- 2000-12-08 IS IS5764A patent/IS5764A/is unknown
- 2000-12-15 NO NO20006431A patent/NO20006431L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ES2188177T3 (es)	2003-06-16
KR20010071541A (ko)	2001-07-28
EP1089742A2 (de)	2001-04-11
DE69904172T2 (de)	2003-08-28
WO1999066913A2 (en)	1999-12-29
PT1089742E (pt)	2003-04-30
PL192118B1 (pl)	2006-09-29
EP1089742B1 (de)	2002-11-27
ITRM980417A0 (it)	1998-06-23
BR9911440A (pt)	2001-03-20
NZ508877A (en)	2002-09-27
CN1306434A (zh)	2001-08-01
WO1999066913A3 (en)	2000-04-20
IT1299191B1 (it)	2000-02-29
NO20006431L (no)	2001-02-22
IS5764A (is)	2000-12-08
JP4430233B2 (ja)	2010-03-10
DK1089742T3 (da)	2003-03-24
HU224957B1 (en)	2006-04-28
NO20006431D0 (no)	2000-12-15
AR018924A1 (es)	2001-12-12
HUP0102879A2 (hu)	2002-03-28
ATE228367T1 (de)	2002-12-15
PL345030A1 (en)	2001-11-19
DE69904172D1 (de)	2003-01-09
AU4390999A (en)	2000-01-10
HUP0102879A3 (en)	2002-12-28
EE200000741A (et)	2002-04-15
MA26655A1 (fr)	2004-12-20
US6335038B1 (en)	2002-01-01
AU755272B2 (en)	2002-12-05
TR200003735T2 (tr)	2001-03-21
TNSN99132A1 (fr)	2005-11-10
JP2002518437A (ja)	2002-06-25
CA2334875C (en)	2009-05-12
ITRM980417A1 (it)	1999-12-23
CA2334875A1 (en)	1999-12-29
IL140163A0 (en)	2002-02-10

Publication	Publication Date	Title
AU755272B2 (en)	2002-12-05	Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome, comprising propionyl-L-carnitine and genistein
US5424331A (en)	1995-06-13	Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis
JB et al.	1997	The effects of phytoestrogens on bone
CA2440261C (en)	2014-05-27	Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids
Bacciottini et al.	2007	Phytoestrogens: food or drug?
US20020182244A1 (en)	2002-12-05	Dietary supplements
US20040220118A1 (en)	2004-11-04	Medical composition for balancing bodily processes
US20040253319A1 (en)	2004-12-16	Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
EP1517667A2 (de)	2005-03-30	Zusammensetzungen und verfahren zur verringerung der entzündungssymptome und/oder biomarkern bei weiblichen patienten
CN101257911A (zh)	2008-09-03	控制脂肪细胞脂肪积聚的方法
EP0934060A1 (de)	1999-08-11	Nahrungszusätze
KR20080068850A (ko)	2008-07-24	레스베라트롤을 포함하는 기능성식품 조성물의 신규한 용도
Cassidy	2003	Dietary phytoestrogens and bone health
CN1330303C (zh)	2007-08-08	金雀异黄素在生产一种治疗骨质疏松症和肥胖症的药物中的用途 ,以及含有金雀异黄素与维生素 d和 k的组合的组合物
US20070059378A1 (en)	2007-03-15	Medical composition for balancing bodily processes
MXPA00012944A (en)	2001-11-21	Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome
CZ20004622A3 (cs)	2001-06-13	Přípravek k prevenci a/nebo léčbě osteoporozy a změn způsobených syndromem menopauzy
US6465021B2 (en)	2002-10-15	Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease
HK1038504A (en)	2002-03-22	Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome, comprising propionyl-l-carnitine and genistein
EP1530968A1 (de)	2005-05-18	Galanginkomponenten zur Erhaltung von gesunden Knochen und/oder Behandlung, Linderung und/oder Vorbeugung von Knochenkrankheiten
MXPA05008573A (es)	2007-02-12	Composicion de isoflavonas para tratamiento de los sintomas y trastornos fisiologicos de la menopausia.
MXPA99001127A (en)	2000-05-01	Dietary supplements